CSTL Stock Overview
A molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus, uveal melanoma, and mental health conditions.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Castle Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.26 |
| 52 Week High | US$25.91 |
| 52 Week Low | US$9.26 |
| Beta | 0.93 |
| 1 Month Change | -4.40% |
| 3 Month Change | 4.26% |
| 1 Year Change | 99.49% |
| 3 Year Change | -65.37% |
| 5 Year Change | n/a |
| Change since IPO | 8.69% |
Recent News & Updates
Recent updates
Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark
Apr 30
Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects
Jan 27Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans
Oct 31Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive
Jun 13Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)
Aug 14Castle Biosciences Q2 2022 Earnings Preview
Aug 08Is There Now An Opportunity In Castle Biosciences, Inc. (NASDAQ:CSTL)?
Aug 05Estimating The Intrinsic Value Of Castle Biosciences, Inc. (NASDAQ:CSTL)
Jun 06Shareholder Returns
| CSTL | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -4.6% | 0.3% | -0.6% |
| 1Y | 99.5% | 1.3% | 22.5% |
Return vs Industry: CSTL exceeded the US Healthcare industry which returned 1.7% over the past year.
Return vs Market: CSTL exceeded the US Market which returned 22.2% over the past year.
Price Volatility
| CSTL volatility | |
|---|---|
| CSTL Average Weekly Movement | 6.5% |
| Healthcare Industry Average Movement | 6.5% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CSTL has not had significant price volatility in the past 3 months.
Volatility Over Time: CSTL's weekly volatility has decreased from 12% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 638 | Derek Maetzold | castlebiosciences.com |
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett’s esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder.
Castle Biosciences, Inc. Fundamentals Summary
| CSTL fundamental statistics | |
|---|---|
| Market cap | US$642.14m |
| Earnings (TTM) | -US$30.80m |
| Revenue (TTM) | US$250.73m |
2.6x
P/S Ratio-20.9x
P/E RatioIs CSTL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CSTL income statement (TTM) | |
|---|---|
| Revenue | US$250.73m |
| Cost of Revenue | US$48.69m |
| Gross Profit | US$202.03m |
| Other Expenses | US$232.83m |
| Earnings | -US$30.80m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.12 |
| Gross Margin | 80.58% |
| Net Profit Margin | -12.28% |
| Debt/Equity Ratio | 2.5% |
How did CSTL perform over the long term?
See historical performance and comparison